

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202jxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 26 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 28 MAY 01 New CAS web site launched
NEWS 29 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display
fields
NEWS 31 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 32 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 33 MAY 21 CA/CAPLUS enhanced with additional kind codes for German
patents
NEWS 34 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese
patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:50:32 ON 07 JUN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 15:51:34 ON 07 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4

DICTIONARY FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\161.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 15:52:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> s l1 full
FULL SEARCH INITIATED 15:53:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 346.00 346.42

FILE 'REGISTRY' ENTERED AT 15:55:27 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4
DICTIONARY FILE UPDATES: 6 JUN 2007 HIGHEST RN 936692-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\161a.str

L4 STRUCTURE UPLOADED

=> d ;4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 14 sss full

FULL SEARCH INITIATED 15:56:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS

27 ANSWERS

SEARCH TIME: 00.00.01

L5 27 SEA SSS FUL L4

=> d 15 1-27

L5 ANSWER 1 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN

RN 892396-78-0 REGISTRY

ED Entered STN: 13 Jul 2006

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with
(α S)- α -ethyl-2-naphthalenemethanamine (1:1) (9CI) (CA INDEX
NAME)

FS STEREOSEARCH

MF C26 H28 O7 S2 . C13 H15 N

SR CA


LC STN Files: CA, CAPLUS

CM 1

CRN 549494-39-5

CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 254437-90-6

CMF C13 H15 N

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 892396-76-8 REGISTRY
ED Entered STN: 13 Jul 2006
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with
(α R)- α -ethyl-1-naphthalenemethanamine (1:1) (9CI) (CA INDEX
NAME)
FS STEREOSEARCH
MF C26 H28 O7 S2 . C13 H15 N
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 549494-39-5
CMF C26 H28 O7 S2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 22038-83-1
CMF C13 H15 N

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 3 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 892396-73-5 REGISTRY
ED Entered STN: 13 Jul 2006
CN Cinchonan-9-ol, (8 α ,9R)-, mono[(-)- α -[[2-(4-
hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benze
nepropanoate] (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H28 O7 S2 . C19 H22 N2 O
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 549494-39-5

CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 485-71-2

CMF C19 H22 N2 O

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 4 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN

RN 891182-81-3 REGISTRY

ED Entered STN: 10 Jul 2006

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with
2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C26 H28 O7 S2 . C4 H11 N

SR CA


LC STN Files: CA, CAPLUS, CASREACT

CM 1

CRN 549494-39-5


CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).



CM 2


CRN 75-64-9
CMF C4 H11 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 5 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 891182-74-4 REGISTRY
ED Entered STN: 10 Jul 2006
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- α -
[(2-phenylethyl)thio]-, (α S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H28 O6 S2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 6 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 840494-28-2 REGISTRY
ED Entered STN: 02 Mar 2005
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, ion(1-) (9CI) (CA INDEX NAME)
MF C26 H27 O7 S2
CI COM
SR CA

PAGE 1-A




PAGE 1-B

—OH

L5 ANSWER 7 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817642-79-8 REGISTRY
 ED Entered STN: 21 Jan 2005
 CN Benzenepropanoic acid, α -[[2-[4-(1,1-dimethylethoxy)phenyl]ethyl]thio]-4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2-[[2-(4-tert-Butoxyphenyl)ethyl]sulfanyl]-3-[4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid
 MF C30 H36 O7 S2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A



PAGE 1-B


—OBU-t

****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 8 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817642-78-7 REGISTRY
 ED Entered STN: 21 Jan 2005
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methanesulfonyl)oxy]-2-(phenylmethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 3-[4-[2-[2-benzyl-4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]-2-[[2-(4-hydroxyphenyl)ethyl]sulfanyl]propionic acid
 MF C33 H34 O7 S2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A




—OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 9 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817642-76-5 REGISTRY
 ED Entered STN: 21 Jan 2005
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethylsulfonyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2-[[2-(4-Hydroxyphenyl)ethylsulfonyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 MF C26 H28 O9 S2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A




PAGE 1-B

—OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 10 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817642-73-2 REGISTRY
 ED Entered STN: 21 Jan 2005
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethylsulfinyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2-[[2-(4-Hydroxyphenyl)ethylsulfinyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 MF C26 H28 O8 S2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



—OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 11 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN

RN 817642-72-1 REGISTRY

ED Entered STN: 21 Jan 2005

CN Benzenepropanoic acid, α-[[2-(3-methoxyphenyl)ethyl]thio]-4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN 2-[[2-(3-Methoxyphenyl)ethyl]thio]-3-[4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid

MF C27 H30 O7 S2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



—OMe

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 12 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN


RN 817642-71-0 REGISTRY

ED Entered STN: 21 Jan 2005

CN Benzenepropanoic acid, α-[[2-(2-fluorophenyl)ethyl]thio]-4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-[[2-(2-Fluorophenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 MF C26 H27 F O6 S2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 13 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817642-69-6 REGISTRY
 ED Entered STN: 21 Jan 2005
 CN Benzenepropanoic acid, α -[[2-[4-(dimethylamino)phenyl]ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2-[[2-[4-(Dimethylamino)phenyl]ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 MF C28 H33 N O6 S2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A



PAGE 1-B

—NMe₂

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 14 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817209-96-4 REGISTRY
 ED Entered STN: 20 Jan 2005
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)
 MF C26 H27 O7 S2 . C5 H14 N O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 840494-28-2

CMF C26 H27 O7 S2

PAGE 1-A



PAGE 1-B

—OH

CM 2

CRN 62-49-7

CMF C5 H14 N O

Me₃⁺N-CH₂-CH₂-OH

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 15 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN

RN 817209-95-3 REGISTRY

ED Entered STN: 20 Jan 2005

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with
tricyclo[3.3.1.1^{3,7}]decan-1-amine (1:1) (9CI) (CA INDEX NAME)

MF C26 H28 O7 S2 . C10 H17 N

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 549494-28-2

CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 768-94-5
CMF C10 H17 N




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 16 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 817209-93-1 REGISTRY
ED Entered STN: 20 Jan 2005
CN L-Lysine, mono[α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]benzenepropanoate] (9CI) (CA INDEX
NAME)
FS STEREOSEARCH
MF C26 H28 O7 S2 . C6 H14 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2




PAGE 1-B

—OH

CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)


1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 17 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817209-92-0 REGISTRY
 ED Entered STN: 20 Jan 2005
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
 [(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-amino-2-
 (hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)
 MF C26 H28 O7 S2 . C4 H11 N O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 549494-28-2
 CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 77-86-1
 CMF C4 H11 N O3




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 18 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 817209-91-9 REGISTRY
 ED Entered STN: 20 Jan 2005
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
 [(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with piperazine (1:1) (9CI)
 (CA INDEX NAME)
 MF C26 H28 O7 S2 . C4 H10 N2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 549494-28-2
 CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 110-85-0
CMF C4 H10 N2




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 19 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 817209-90-8 REGISTRY
ED Entered STN: 20 Jan 2005
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-methyl-2-propanamine
(1:1) (9CI) (CA INDEX NAME)
MF C26 H28 O7 S2 . C4 H11 N
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2


CRN 75-64-9
CMF C4 H11 N



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 20 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 817181-58-1 REGISTRY
ED Entered STN: 20 Jan 2005
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H28 O7 S2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 21 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 815608-42-5 REGISTRY
ED Entered STN: 18 Jan 2005
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, sodium salt, (α S)- (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C26 H28 O7 S2 . x Na
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (549494-39-5)

Absolute stereochemistry. Rotation (-).




● x Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 22 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 815608-41-4 REGISTRY
ED Entered STN: 18 Jan 2005
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, potassium salt, (α S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H28 O7 S2 . x K
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (549494-39-5)

Absolute stereochemistry. Rotation (-).




● x K

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 23 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 549494-39-5 REGISTRY
ED Entered STN: 17 Jul 2003
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H28 O7 S2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 24 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 549494-32-8 REGISTRY
ED Entered STN: 17 Jul 2003
CN Benzenepropanoic acid, α -[[2-(4-chlorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H27 Cl O6 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 25 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 549494-29-3 REGISTRY
ED Entered STN: 17 Jul 2003
CN Benzenepropanoic acid, α -[[2-(4-fluorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
MF C26 H27 F O6 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A




PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 26 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 549494-28-2 REGISTRY
ED Entered STN: 17 Jul 2003
CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
MF C26 H28 O7 S2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

PAGE 1-A



PAGE 1-B


—OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 27 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN
RN 549494-27-1 REGISTRY
ED Entered STN: 17 Jul 2003
CN Benzenepropanoic acid, α -[[2-(4-chlorophenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
MF C26 H27 Cl O6 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 1-B

—Cl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

225.65

572.07

FILE 'CAPLUS' ENTERED AT 15:57:22 ON 07 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2007 VOL 146 ISS 24

FILE LAST UPDATED: 6 Jun 2007 (20070606/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 15:50:32 ON 07 JUN 2007)

FILE 'REGISTRY' ENTERED AT 15:51:34 ON 07 JUN 2007

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS FULL

L3 0 S L1 FULL

FILE 'REGISTRY' ENTERED AT 15:55:27 ON 07 JUN 2007

L4 STRUCTURE UPLOADED

L5 27 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:57:22 ON 07 JUN 2007

=> s 15 ibib ab hitstr tot

MISSING OPERATOR L5 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s 15

L6 7 L5

=> d 16 ibib ab hitstr tot

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:608744 CAPLUS

DOCUMENT NUMBER: 145:83117

TITLE: Preparation of amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-

((methylsulfonyl)oxy) phenoxy)ethyl)phenyl) propanoic acid for treating lipid disorders

INVENTOR(S): Snape, Evan William
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064232	A1	20060622	WO 2005-GB4829	20051214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: GB 2004-27701 A 20041217

AB A cinchonidine salt, an (R)-(+)-1-(1-naphthyl)ethylamine salt and a (S)-(-)-1-(2-naphthyl)ethylamine salt of the title compound (I) processes for their preparation, their use in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical compns. containing them, are described.

IT 892396-73-5P 892396-76-8P 892396-78-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy) phenoxy)ethyl)phenyl) propanoic acid for treating lipid disorders)

RN 892396-73-5 CAPLUS


CN Cinchonan-9-ol, (8 α ,9R)-, mono[(-)- α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benzene neopropanoate] (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-39-5

CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 485-71-2

CMF C19 H22 N2 O

Absolute stereochemistry. Rotation (-).



RN 892396-76-8 CAPLUS


CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with
(α R)- α -ethyl-1-naphthalenemethanamine (1:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 549494-39-5

CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 22038-83-1

CMF C13 H15 N

Absolute stereochemistry.



RN 892396-78-0 CAPLUS


CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with
(α S)- α -ethyl-2-naphthalenemethanamine (1:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 549494-39-5

CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 254437-90-6

CMF C13 H15 N

Absolute stereochemistry.



IT 549494-39-5


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy)phenoxy)ethyl)phenyl)propanoic acid for treating lipid disorders)

RN 549494-39-5 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:608672 CAPLUS

DOCUMENT NUMBER: 145:61508

TITLE: Chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivatives

INVENTOR(S): Brown, David; Gilday, John Peter; Hopes, Philip Anthony; Moseley, Jonathan David; Snape, Evan William; Wells, Andrew

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064213	A2	20060622	WO 2005-GB4800	20051214
WO 2006064213	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-27524 A 20041216

OTHER SOURCE(S): CASREACT 145:61508; MARPAT 145:61508


AB Enzymic and chemical processes for the preparation of certain of 3-phenyl-2-arylalkylthiopropionic acid derivs. which have utility in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome are described and also certain novel intermediates used in these processes.

IT 891182-74-4DP, and pharmaceutically acceptable salts of
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)

RN 891182-74-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- α -[(2-phenylethyl)thio]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 549494-39-5P

RL: BPN (Biosynthetic preparation); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)

RN 549494-39-5 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 817181-58-1P

RL: BYP (Byproduct); PREP (Preparation)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid
derivs.)

RN 817181-58-1 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 891182-81-3P

RL: CPS (Chemical process); PEP (Physical, engineering or chemical
process); PRP (Properties); PUR (Purification or recovery); RCT
(Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC
(Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid
derivs.)

RN 891182-81-3 CAPLUS


CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with
2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-39-5

CMF C26 H28 O7 S2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N




IT 549494-28-2

RL: CPS (Chemical process); PEP (Physical, engineering or chemical
process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid
derivs.)

RN 549494-28-2 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH

IT 817209-90-8P
 RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
 (chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
 RN 817209-90-8 CAPLUS
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 549494-28-2
 CMF C26 H28 O7 S2


PAGE 1-A



PAGE 1-B

—OH

CM 2
 CRN 75-64-9
 CMF C4 H11 N



ACCESSION NUMBER: 2004:1154663 CAPLUS
 DOCUMENT NUMBER: 142:93390
 TITLE: Process for the preparation of racemic
 [(hydroxyphenyl)ethylthio]propanoic acid derivative,
 useful as selective PPAR α modulator
 INVENTOR(S): Andersson, Kjell; Lindstedt-Astermark, Eva-Lotte;
 Sorensen, Henrik
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
 SOURCE: PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113285	A1	20041229	WO 2004-GB2599	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249487	A1	20041229	AU 2004-249487	20040616
CA 2529252	A1	20041229	CA 2004-2529252	20040616
EP 1638929	A1	20060329	EP 2004-736920	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011450	A	20060718	BR 2004-11450	20040616
CN 1835918	A	20060920	CN 2004-80023145	20040616
JP 2006527751	T	20061207	JP 2006-516435	20040616
NO 2005005883	A	20060109	NO 2005-5883	20051212
US 2006167309	A1	20060727	US 2005-561161	20051216
PRIORITY APPLN. INFO.:			GB 2003-14260	A 20030619
			WO 2004-GB2599	W 20040616

OTHER SOURCE(S): CASREACT 142:93390; MARPAT 142:93390

AB The invention provides a process for preparation of racemic
 [(hydroxyphenyl)ethylthio]propanoic acid derivative of formula I, useful as
 selective PPAR α modulator (no biol. data). The racemic title compound
 I was prepared via thiolation of 2-chloropropanoate derivative II by
 2-[4-(benzyloxy)phenyl]ethanethiol, debenzoylation, and hydrolysis.
 Resolution of I gave (-)-I and (+)-I. (+)-Enantiomer was used as a starting
 material for racemization reaction.

IT 549494-39-5P


RL: IMF (Industrial manufacture); PUR (Purification or recovery); SPN
 (Synthetic preparation); PREP (Preparation)

(process for the preparation of racemic [(hydroxyphenyl)ethylthio]propanoic acid derivative useful as selective PPAR α modulator)

RN 549494-39-5 CAPLUS


CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
 [(methylsulfonyl)oxy]phenoxy]ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 549494-28-2P 817181-58-1P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for the preparation of racemic [(hydroxyphenyl)ethylthio]propanoic acid derivative useful as selective PPAR α modulator)
 RN 549494-28-2 CAPLUS
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH

RN 817181-58-1 CAPLUS
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:1154662 CAPLUS
 DOCUMENT NUMBER: 142:86664
 TITLE: Potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid and their use in medicine
 INVENTOR(S): Ahlqvist, Matti; Bohlin, Martin Hans
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113284	A1	20041229	WO 2004-GB2595	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249485	A1	20041229	AU 2004-249485	20040616
CA 2529251	A1	20041229	CA 2004-2529251	20040616
EP 1641749	A1	20060405	EP 2004-742954	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011515	A	20060801	BR 2004-11515	20040616
CN 1835920	A	20060920	CN 2004-80023294	20040616
JP 2006527750	T	20061207	JP 2006-516434	20040616
NO 2005005927	A	20060127	NO 2005-5927	20051213
US 2007099997	A1	20070503	US 2005-561170	20051216
PRIORITY APPLN. INFO.: GB 2003-14131 A 20030618 WO 2004-GB2595 W 20040616				
AB	A potassium salt or a sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid, processes for their preparation, their use in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical compns. containing them.			
IT	815608-41-4P 815608-42-5P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid for therapeutic use)			
RN	815608-41-4 CAPLUS			
CN	Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, potassium salt, (α S)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry. Rotation (-).




●x K

RN 815608-42-5 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, sodium salt, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● x Na


IT 549494-39-5P

RL: PUR (Purification or recovery); PREP (Preparation)
(preparation of potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid for therapeutic use)

RN 549494-39-5 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 549494-28-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid for therapeutic use)

RN 549494-28-2 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1154661 CAPLUS

DOCUMENT NUMBER: 142:93515

TITLE: A preparation of amine salts of
[(phenoxyethyl)phenyl]propanoic acid derivative,
useful for the treatment of lipid disorders

INVENTOR(S): Ahlqvist, Matti; Dahlstrom, Mikael Ulf Johan; Ohlsson,

Bengt; Storey, Richard Anthony; Taylor, Nigel Philip;
 Woods, Rebecca
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113283	A1	20041229	WO 2004-GB2576	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249483	A1	20041229	AU 2004-249483	20040616
CA 2529544	A1	20041229	CA 2004-2529544	20040616
EP 1638930	A1	20060329	EP 2004-736922	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011580	A	20060808	BR 2004-11580	20040616
CN 1835919	A	20060920	CN 2004-80023146	20040616
JP 2006527749	T	20061207	JP 2006-516428	20040616
NO 2005006006	A	20060224	NO 2005-6006	20051216
US 2007099928	A1	20070503	US 2005-561222	20051219
PRIORITY APPLN. INFO.:			GB 2003-14130	A 20030618
			WO 2004-GB2576	W 20040616

AB The invention relates to a preparation of tert-butylamine salt, piperazine salt, choline salt, tris(hydroxymethyl)methylamine salt, lysine salt, or adamantylamine salt of [(phenoxyethyl)phenyl]propanoic acid derivative of formula (-)-I, useful in the treatment of lipid disorders (no biol. data). Tert-Butylamine salt of (-)-I was prepared from (-)-I and tert-butylamine with a yield of 68% (example 1).

IT 817209-90-8P 817209-91-9P 817209-92-0P
 817209-93-1P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative useful for the treatment of lipid disorders)

RN 817209-90-8 CAPLUS


CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2

CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 75-64-9

CMF C4 H11 N



RN 817209-91-9 CAPLUS


CM Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with piperazine (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 549494-28-2

CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 110-85-0

CMF C4 H10 N2



RN 817209-92-0 CAPLUS


CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2

CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 77-86-1

CMF C4 H11 N O3



RN 817209-93-1 CAPLUS


CN L-Lysine, mono[α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2

CMF C26 H28 O7 S2

PAGE 1-A




—OH

CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



IT 817209-95-3P 817209-96-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative useful for the treatment of lipid disorders)

RN 817209-95-3 CAPLUS


CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with tricyclo[3.3.1.1^{3,7}]decan-1-amine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2

CMF C26 H28 O7 S2

PAGE 1-A




PAGE 1-B

—OH

CM 2

CRN 768-94-5

CMF C10 H17 N



RN 817209-96-4 CAPLUS


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840494-28-2

CMF C26 H27 O7 S2

PAGE 1-A



PAGE 1-B

—OH

CM 2

CRN 62-49-7

CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$


IT 549494-39-5P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative
useful for the treatment of lipid disorders)

RN 549494-39-5 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 549494-28-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
 (preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid
 derivative
 useful for the treatment of lipid disorders)
 RN 549494-28-2 CAPLUS
 CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-
 [(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OH

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:1154660 CAPLUS
 DOCUMENT NUMBER: 142:93534
 TITLE: Substituted 3-phenylpropionic acid derivatives with
 PPAR α and PPAR δ modulatory activities,
 useful as therapeutic agents for treatment of
 dyslipidemia, and their preparation, pharmaceutical
 compositions, and methods of use
 INVENTOR(S): Lindstedt-Alstermark, Eva-Lotte; Boije, Anna Maria
 Persdotter; Holm, Patrik
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113282	A1	20041229	WO 2004-GB2554	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249474	A1	20041229	AU 2004-249474	20040616
CA 2529297	A1	20041229	CA 2004-2529297	20040616
EP 1638927	A1	20060329	EP 2004-736926	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

BR 2004011536	A	20060801	BR 2004-11536	20040616
CN 1835917	A	20060920	CN 2004-80023273	20040616
JP 2006527747	T	20061207	JP 2006-516423	20040616
NO 2005006005	A	20060224	NO 2005-6005	20051216
US 2006199857	A1	20060907	US 2005-561126	20051216
PRIORITY APPLN. INFO.:			GB 2003-14075	A 20030618
			WO 2004-GB2554	W 20040616

OTHER SOURCE(S): MARPAT 142:93534

AB Substituted 3-phenylpropionic acid derivs. I are disclosed [R = H, OH or NH or their derivs.; R1 = alk(en/yn)yl, aryl, cyano, OH or SH or CO2H or their derivs.; R2 = H, alkyl, aryl, alkylaryl; R3, R4 = (independently) H, alkyl, aryl, alkylaryl; or R2R4 = pi bond; n = 1-6; m = 0 or 1; D's = H or wide variety of substituents; T = O, S, or N(X) with some restrictions; X = alkyl or alkylaryl; with 2' complex provisos]. Also disclosed are (1) processes for preparing I, (2) their utility in treating clin. conditions including lipid disorders (dyslipidemias), whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, (3) methods for their therapeutic use, and (4) pharmaceutical compns. containing them. I were tested in the assays described in WO 03/051821 (no data). I show superior potency in vitro, higher affinity, and/or higher in vivo efficacy. I also have a better selectivity profile, which is expected to improve in vivo safety. In addition, I may have improved DMPK (drug metabolism and pharmacokinetic) properties, for example improved metabolic stability in vitro or bioavailability. The compds. also have an improved solubility and/or a promising toxicol. profile. I may be combined with other therapeutic agents that are useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidemias, dyslipidemias, diabetes and obesity. Twelve examples were prepared and/or claimed. For instance, compound II was prepared by: (1) thioetherification of 4-(PhCH2O)C6H4CH2CH2SH with ClCH(CO2Me)CH2C6H4(CH2CH2OH)-4 (40%); (2) Mitsunobu etherification of the product alc. with 4-benzoylphenol (83%); (3) debenzylation (78%); and (4) saponification of the ester with LiOH (49%). The EC50 of II for human PPAR α was 0.78 μ M.


IT 817642-69-6P, 2-[[2-[4-(Dimethylamino)phenyl]ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 817642-71-0P, 2-[[2-(2-Fluorophenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 817642-72-1P, 2-[[2-(3-Methoxyphenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 817642-73-2P, 2-[[2-(4-Hydroxyphenyl)ethyl]sulfinyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 817642-76-5P, 2-[[2-(4-Hydroxyphenyl)ethyl]sulfonyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid
 817642-78-7P, 3-[4-[2-[2-Benzyl-4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]-2-[[2-(4-hydroxyphenyl)ethyl]sulfanyl]propionic acid
 817642-79-8P, 2-[[2-(4-Tert-Butoxyphenyl)ethyl]sulfanyl]-3-[4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted phenylpropionic acid derivs. as PPAR α and PPAR δ modulators for treatment of dyslipidemia)

RN 817642-69-6 CAPLUS

CN Benzenepropanoic acid, α -[[2-[4-(dimethylamino)phenyl]ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NMe₂

RN 817642-71-0 CAPLUS


CN Benzenepropanoic acid, α-[[2-(2-fluorophenyl)ethyl]thio]-4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 817642-72-1 CAPLUS

CN Benzenepropanoic acid, α-[[2-(3-methoxyphenyl)ethyl]thio]-4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 817642-73-2 CAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]sulfinyl]-4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




—OH

RN 817642-76-5 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]sulfonyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH

RN 817642-78-7 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]-2-(phenylmethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH

RN 817642-79-8 CAPLUS

CN Benzenepropanoic acid, α -[[2-[4-(1,1-dimethylethoxy)phenyl]ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



— OBU-t

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:491173 CAPLUS
 DOCUMENT NUMBER: 139:69050
 TITLE: Preparation of 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR- α
 INVENTOR(S): Alstermark Lindstedt, Eva-Lotte; Persdotter Boije, Anna Maria; Holm, Patrik
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051826	A1	20030626	WO 2002-GB5743	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470066	A1	20030626	CA 2002-2470066	20021218
CA 2470066	C	20070410		
AU 2002352426	A1	20030630	AU 2002-352426	20021218
EP 1458677	A1	20040922	EP 2002-788144	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015090	A	20041116	BR 2002-15090	20021218
HU 200402093	A2	20050228	HU 2004-2093	20021218
JP 2005511785	T	20050428	JP 2003-552714	20021218
JP 3810770	B2	20060816		
CN 1620430	A	20050525	CN 2002-828122	20021218
NZ 533365	A	20060526	NZ 2002-533365	20021218
ZA 2004004585	A	20051026	ZA 2004-4585	20040609
IN 2004DN01629	A	20070420	IN 2004-DN1629	20040610
NO 2004003084	A	20040716	NO 2004-3084	20040716
US 2005215630	A1	20050929	US 2005-499042	20050328
JP 2006241162	A	20060914	JP 2006-77296	20060320
PRIORITY APPLN. INFO.:			SE 2001-4333	A 20011219
			JP 2003-552714	A3 20021218
			WO 2002-GB5743	W 20021218
OTHER SOURCE(S): MARPAT 139:69050				
AB 4-(4-MeSO ₃ C ₆ H ₄ OCH ₂ CH ₂)C ₆ H ₄ CH ₂ CH(CO ₂ H)CH ₂ CH ₂ C ₆ H ₄ R-4 [I, R = Cl, F, OH] and optical isomers and racemates thereof were prepared for use in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance. I have EC ₅₀ ≤ 5 μmol/L for PPAR- α and the ratio EC ₅₀ (PPAR- γ):EC ₅₀ (PPAR- α) > 25:1. Thus, I [R = Cl] was prepared from 4-(4-MeSO ₃ C ₆ H ₄ OCH ₂ CH ₂)C ₆ H ₄ CH ₂ CH(CO ₂ H)Cl				

and 4-ClC₆H₄CH₂CH₂SH.

IT 549494-32-8P 549494-39-5P


RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR- α)

RN 549494-32-8 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-chlorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 549494-39-5 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 549494-27-1P 549494-28-2P 549494-29-3P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR- α)

RN 549494-27-1 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-chlorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

RN 549494-28-2 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH

RN 549494-29-3 CAPLUS

CN Benzenepropanoic acid, α -[[2-(4-fluorophenyl)ethyl]thio]-4-[2-[4-(methylsulfonyl)oxy]phenoxy]ethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—F

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202jxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/Capplus Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/Capplus updated with revised CAS roles
NEWS 7 JAN 22 CA/Capplus enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 26 APR 30 CA/Capplus enhanced with 1870-1889 U.S. patent records
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 28 MAY 01 New CAS web site launched
NEWS 29 MAY 08 CA/Capplus Indian patent publication number format defined
NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display
fields
NEWS 31 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 32 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 33 MAY 21 CA/Capplus enhanced with additional kind codes for German
patents
NEWS 34 MAY 22 CA/Capplus enhanced with IPC reclassification in Japanese
patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:14:44 ON 07 JUN 2007

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 14:15:01 ON 07 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2007 VOL 146 ISS 24

FILE LAST UPDATED: 6 Jun 2007 (20070606/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s wo 2003051826/pn

L1 1 WO 2003051826/PN

(WO2003051826/PN)

=> d l1 iall

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:491173 CAPLUS

DOCUMENT NUMBER: 139:69050

ENTRY DATE: Entered STN: 27 Jun 2003

TITLE: Preparation of 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR- α

INVENTOR(S): Alstermark Lindstedt, Eva-Lotte; Persdotter Boije, Anna Maria; Holm, Patrik

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

INT. PATENT CLASSIF.:

MAIN: C07C323-56

SECONDARY: A61K031-192

CLASSIFICATION: 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051826	A1	20030626	WO 2002-GB5743	20021218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470066	A1	20030626	CA 2002-2470066	20021218
CA 2470066	C	20070410		
AU 2002352426	A1	20030630	AU 2002-352426	20021218
EP 1458677	A1	20040922	EP 2002-788144	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015090	A	20041116	BR 2002-15090	20021218
HU 200402093	A2	20050228	HU 2004-2093	20021218
JP 2005511785	T	20050428	JP 2003-552714	20021218
JP 3810770	B2	20060816		
CN 1620430	A	20050525	CN 2002-828122	20021218
NZ 533365	A	20060526	NZ 2002-533365	20021218
ZA 2004004585	A	20051026	ZA 2004-4585	20040609
IN 2004DN01629	A	20070420	IN 2004-DN1629	20040610
NO 2004003084	A	20040716	NO 2004-3084	20040716
US 2005215630	A1	20050929	US 2005-499042	20050328
JP 2006241162	A	20060914	JP 2006-77296	20060320
PRIORITY APPLN. INFO.:			SE 2001-4333	A 20011219
			JP 2003-552714	A3 20021218
			WO 2002-GB5743	W 20021218

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003051826	ICM	C07C323-56
	ICS	A61K031-192
	IPCI	C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*]; A61K0031-192 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*]; A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A]; C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S]; C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A]
	ECLA	C07C323/56
CA 2470066	IPCI	A61K0031-192 [I,A]; A61K0031-185 [I,C*]; A61K0031-255 [I,A]; A61K0031-21 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,A]; A61K0045-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0003-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12

		[I,A]; A61P0009-00 [I,C*]; C07C0309-66 [I,A]; C07C0309-00 [I,C*]; C07C0319-20 [I,A]; C07C0319-00 [I,C*]; C07C0323-56 [I,A]; C07C0323-00 [I,C*]
	IPCR	A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*]; A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A]; C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S]; C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A]
	ECLA	C07C323/56
AU 2002352426	IPCI	C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*]; A61K0031-192 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*]; A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A]; C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S]; C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A]
EP 1458677	IPCI	C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*]; A61K0031-192 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*]; A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A]; C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S]; C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A]
	ECLA	C07C323/56
BR 2002015090	IPCI	C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*]; A61K0031-192 [ICS,7]; A61K0031-185 [ICS,7,C*]
	IPCR	A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*]; A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A]; C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S]; C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A]
	ECLA	C07C323/56
HU 200402093	IPCI	C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*]
JP 2005511785	IPCI	C07C0323-56 [I,A]; C07C0323-00 [I,C*]; A61K0031-255 [I,A]; A61K0031-21 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,A]; A61K0045-00 [I,A]; A61P0003-04

[I,A]; A61P0003-06 [I,A]; A61P0003-00 [I,C*];
A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0009-00
[I,C*]; C07C0309-66 [I,A]; C07C0309-00 [I,C*];
C07C0319-20 [I,A]; C07C0319-00 [I,C*]

IPCR A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21
[I,C*]; A61K0031-255 [I,A]; A61K0031-366 [I,A];
A61K0031-366 [I,C*]; A61K0031-40 [I,A]; A61K0031-40
[I,C*]; A61K0045-00 [I,A]; A61K0045-00 [I,C*];
A61P0003-00 [I,C*]; A61P0003-04 [I,A]; A61P0003-06
[I,A]; A61P0003-10 [I,A]; A61P0009-00 [I,C*];
A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C0309-00
[I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*];
C07C0319-20 [I,A]; C07C0323-00 [I,C*]; C07C0323-56
[I,A]; C07D [I,S]

FTERM 4C084/AA19; 4C084/ZA42; 4C084/ZA45; 4C084/ZA70;
4C084/ZC33; 4C084/ZC35; 4C086/AA01; 4C086/BA17;
4C086/BC05; 4C086/MA02; 4C086/MA04; 4C086/NA05;
4C086/ZA42; 4C086/ZA45; 4C086/ZA70; 4C086/ZC33;
4C086/ZC35; 4C086/ZC75; 4C206/AA01; 4C206/AA03;
4C206/JA06; 4C206/KA01; 4C206/KA17; 4C206/MA01;
4C206/MA02; 4C206/MA04; 4C206/NA14; 4C206/ZA42;
4C206/ZA45; 4C206/ZA70; 4C206/ZC33; 4C206/ZC35;
4H006/AA01; 4H006/AA02; 4H006/AA03; 4H006/AB20;
4H006/AB23; 4H006/AB27; 4H006/AB84; 4H006/AC46;
4H006/TA04; 4H006/TB53

CN 1620430 IPCI C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*];
A61K0031-192 [ICS,7]; A61K0031-185 [ICS,7,C*]

IPCR A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185
[I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*];
A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366
[I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A];
A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04
[I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12
[I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66
[I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A];
C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S];
C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435
[I,C*]; C07K0014-705 [I,A]

NZ 533365 ECLA C07C323/56

IPCI C07C0323-56 [ICS,7]; C07C0323-00 [ICS,7,C*];
A61K0031-192 [ICS,7]; A61K0031-185 [ICS,7,C*]

IPCR A61K0031-185 [I,C*]; A61K0031-21 [I,C*]; A61K0031-366
[I,C*]; A61K0031-40 [I,C*]; A61K0045-00 [I,C*];
A61P0003-00 [I,C*]; A61P0009-00 [I,C*]; C07C0309-00
[I,C*]; C07C0319-00 [I,C*]; C07C0323-00 [I,C*];
C07D0221-00 [I,C*]; C07K0014-435 [I,C*]; A61K0031-192
[I,A]; A61K0031-255 [I,A]; A61K0031-366 [I,A];
A61K0031-40 [I,A]; A61K0045-00 [I,A]; A61P0003-00
[I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A];
A61P0003-10 [I,A]; A61P0009-10 [I,A]; A61P0009-12
[I,A]; C07C0309-66 [I,A]; C07C0319-20 [I,A];
C07C0323-56 [I,A]; C07D0221-18 [I,A]; C07K0014-705
[I,A]

ZA 2004004585 ECLA C07C323/56

IPCI C07C [ICS,7]; A61K [ICS,7]

IPCR A61K0045-00 [I,C*]; A61K0031-185 [I,C*]; A61K0031-21
[I,C*]; A61K0031-366 [I,C*]; A61K0031-40 [I,C*];
A61P0003-00 [I,C*]; A61P0009-00 [I,C*]; C07C0309-00
[I,C*]; C07C0319-00 [I,C*]; C07C0323-00 [I,C*];
C07D0221-00 [I,C*]; C07K0014-435 [I,C*]; A61K0045-00
[I,A]; A61K0031-192 [I,A]; A61K0031-255 [I,A];
A61K0031-366 [I,A]; A61K0031-40 [I,A]; A61P0003-00
[I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A];

A61P0003-10 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C0309-66 [I,A]; C07C0319-20 [I,A]; C07C0323-56 [I,A]; C07D0221-18 [I,A]; C07K0014-705 [I,A]
 ECLA C07C323/56
 IN 2004DN01629 IPCI C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*]
 NO 2004003084 IPCI C07C0323-56 [ICM,7]; C07C0323-00 [ICM,7,C*];
 A61K0031-192 [ICS,7]; A61K0031-185 [ICS,7,C*];
 A61P0003-06 [ICS,7]; A61P0003-10 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
 IPCR A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*];
 A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A];
 A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
 A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A];
 C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S]; C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A]
 ECLA C07C323/56
 US 2005215630 IPCI A61K0031-255 [ICM,7]; A61K0031-21 [ICM,7,C*]
 IPCR A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*];
 A61K0031-255 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A];
 A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
 A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; C07C [I,S]; C07C0309-00 [I,C*]; C07C0309-66 [I,A]; C07C0319-00 [I,C*]; C07C0319-20 [I,A];
 C07C0323-00 [I,C*]; C07C0323-56 [I,A]; C07D [I,S]; C07D0221-00 [I,C*]; C07D0221-18 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A]
 NCL 514/517.000; 558/052.000
 ECLA C07C323/56
 JP 2006241162 IPCI A61K0031-255 [I,A]; A61K0031-21 [I,C*]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0003-00 [I,C*];
 A61K0045-00 [I,A]; C07C0323-56 [N,A]; C07C0323-00 [N,C*]
 FTERM 4C084/AA19; 4C084/MA02; 4C084/NA14; 4C084/ZA422; 4C084/ZA452; 4C084/ZA702; 4C084/ZC331; 4C084/ZC332; 4C084/ZC351; 4C084/ZC352; 4C206/AA01; 4C206/AA02; 4C206/AA03; 4C206/JA66; 4C206/KA01; 4C206/MA02; 4C206/MA03; 4C206/MA05; 4C206/NA14; 4C206/ZA42; 4C206/ZA70; 4C206/ZC02; 4C206/ZC33; 4C206/ZC35; 4H006/AA01; 4H006/AA03; 4H006/AB20; 4H006/AB27; 4H006/TA04; 4H006/TB02; 4H006/TB40; 4H006/TB53; 4H006/TC32; 4H006/TC36
 OTHER SOURCE(S): MARPAT 139:69050

ABSTRACT:

4-(4-MeSO₃C₆H₄OCH₂CH₂)C₆H₄CH₂CH(CO₂H)CH₂CH₂C₆H₄R-4 [I, R = Cl, F, OH] and optical isomers and racemates thereof were prepared for use in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance. I have EC₅₀ ≤ 5 μmol/L for PPAR-α and the ratio EC₅₀(PPAR-γ):EC₅₀(PPAR-α) > 25:1. Thus, I [R = Cl] was prepared from 4-(4-MeSO₃C₆H₄OCH₂CH₂)C₆H₄CH₂CH(CO₂H)Cl and 4-ClC₆H₄CH₂CH₂SH.

SUPPL. TERM: aralkylthiophenylpropanoic acid prepn peroxisome proliferator activated receptor modulator

INDEX TERM: Dyslipidemia

ROLE: BSU (Biological study, unclassified); BIOL (Biological

study)
 (preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs.
 as selective agonists of PPAR- α)

INDEX TERM: Peroxisome proliferator-activated receptors
 ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
 (α ; preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR- α)

INDEX TERM: 549494-32-8P 549494-39-5P
 ROLE: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR- α)

INDEX TERM: 96-33-3, Methyl acrylate 103-16-2, 4-Benzoyloxyphenol
 104-10-9, 2-(4-Aminophenyl)ethanol 332-43-4,
 1-(2-Chloroethyl)-4-fluorobenzene 507-09-5, Thioacetic acid, reactions 32327-70-1, 1-Chloro-4-(2-Chloroethyl)benzene 549494-36-2
 ROLE: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR- α)

INDEX TERM: 455267-22-8P 549494-30-6P 549494-31-7P 549494-33-9P
 549494-34-0P 549494-35-1P 549494-37-3P 549494-38-4P
 549494-40-8P
 ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR- α)

INDEX TERM: 549494-27-1P 549494-28-2P 549494-29-3P
 ROLE: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR- α)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S): (1) Astra; WO 9962871 A 1999 CAPLUS
 (2) Astra; WO 9962872 A 1999 CAPLUS